The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Overcoming challenges in TCR mapping for personalized immunotherapy in multiple myeloma
David Avigan, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, discusses the technical challenges of translating antigen receptor (TCR) mapping into clinical practice. He highlights limitations in current HLA-restricted approaches and peptide selection, while noting the potential for artificial intelligence (AI) and improved databases to identify reliable antigen pairs and help guide treatment decisions. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
